Sezary syndrome
Drug research and approvals for sezary syndrome: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 19 studies of sezary syndrome are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 19
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 1
- A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin LymphomaNCT07192471 · Phase 1 · Kyowa Kirin, Inc. · starts Sep 2, 2026
- Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result SurveillanceNCT07132567 · Not reported · Kyowa Kirin Co., Ltd. · starts May 2, 2025
- A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or…NCT07003100 · Not reported · City of Hope Medical Center · starts Dec 6, 2024
- A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCLNCT06854653 · Phase 2 · Prescient Therapeutics, Ltd. · starts Mar 28, 2025
- Systemic Therapies in the Treatment of Cutaneous T-cell LymphomaNCT06588868 · Not reported · Fondazione Italiana Linfomi - ETS · starts Feb 27, 2025
- A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell LymphomaNCT06436677 · Not reported · Peking University First Hospital · starts May 9, 2024
- Novel Flow-cytometry Approaches to Improve the Detection of Tumor Cells in CTCLNCT06382844 · Not reported · Instituto de Investigación Biomédica de Salamanca · starts Jan 1, 2024
- A Registry for People With T-cell LymphomaNCT05978141 · Not reported · Memorial Sloan Kettering Cancer Center · starts Jul 27, 2023
- Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell LymphomasNCT05956041 · Phase 2 · University of Michigan Rogel Cancer Center · starts Dec 6, 2023
Approved 1
- MogamulizumabC-C chemokine receptor type 4 cross-linking agent
Phase 3 2
- NaloxoneOpioid receptors; mu/kappa/delta antagonist
- ZanolimumabT-cell surface antigen CD4 other
Phase 2 12 of 18
- PembrolizumabProgrammed cell death protein 1 inhibitor
- AlemtuzumabCAMPATH-1 antigen inhibitor
- BexaroteneRetinoid X receptor agonist
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- TacrolimusFK506-binding protein 1A inhibitor
- Brentuximab vedotinTubulin inhibitor
- Edodekin alfa
- Resminostat
- DoxycyclineMatrix metalloproteinase 7 inhibitor
- MethotrexateDihydrofolate reductase inhibitor
- MethoxsalenDNA inhibitor
- NelarabineDNA inhibitor
Phase 1 or earlier 12 of 20
- Fludarabine
- TanespimycinHeat shock protein HSP90 inhibitor
- CyclosporineCyclophilin A modulator
- IrinotecanDNA topoisomerase I inhibitor
- AldesleukinInterleukin-2 receptor agonist
- DuvelisibPI3-kinase p110-delta subunit inhibitor
- DasatinibTyrosine-protein kinase ABL inhibitor
- PralatrexateDihydrofolate reductase inhibitor
- CarmustineGlutathione reductase inhibitor
- RomidepsinHistone deacetylase inhibitor
- Carfilzomib26S proteasome inhibitor
- Bortezomib26S proteasome inhibitor
How its trials ended
155 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 54 whose ending is known, 33% met their primary endpoint, 0% missed it and 67% stopped early.
- Completed, result not reported7146%
- Ongoing2617%
- Met its primary endpoint1812%
- Stopped: other or unclear1510%
- Stopped: enrollment or feasibility117%
- Stopped: sponsor or business decision64%
- Stopped: funding43%
- Status unknown43%
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Nov 22, 2018 | PoteligeoMogamulizumab · orphan | Kyowa Kirin Holdings B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA